Exelixis Stock Today

EXEL Stock  USD 23.86  0.25  1.06%   

Performance

0 of 100

 
Low
 
High
Very Weak

Odds Of Distress

Less than 3

 
100  
 
Zero
Very Low
Exelixis is selling for 23.86 as of the 28th of March 2024. This is a 1.06 percent increase since the beginning of the trading day. The stock's lowest day price was 23.66. Exelixis has a very small chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. Equity ratings for Exelixis are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 27th of February 2024 and ending today, the 28th of March 2024. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
7th of April 2000
Category
Healthcare
Classification
Health Care
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California. The company has 303.19 M outstanding shares of which 8.25 M shares are currently shorted by private and institutional investors with about 3.82 trading days to cover. More on Exelixis

Moving against Exelixis Stock

  0.71URGN UroGen Pharma Financial Report 9th of May 2024 PairCorr
  0.61MRK Merck Company Fiscal Quarter End 31st of March 2024 PairCorr
  0.55MGNX MacroGenics Financial Report 14th of May 2024 PairCorr
  0.48VBIV VBI Vaccines Financial Report 20th of May 2024 PairCorr
  0.46DMAC DiaMedica Therapeutics Financial Report 20th of May 2024 PairCorr

Exelixis Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Exelixis' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Exelixis or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
CEO and President and DirectorMichael Morrissey
Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, ARCA Biotechnology, NASDAQ Composite, SP Midcap 400, NASDAQ Composite Total, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors)
Average Analyst Recommendation
Analysts covering Exelixis report their recommendations after researching Exelixis' financial statements, talking to executives and customers, or listening in on Exelixis' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Exelixis. The Exelixis consensus assessment is calculated by taking the average forecast from all of the analysts covering Exelixis.
Financial Strength
Based on the key indicators related to Exelixis' liquidity, profitability, solvency, and operating efficiency, Exelixis is doing better financially then in previous quarter. It has a moderate odds of reporting better financial numbers in April. Financial strength of Exelixis is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover0.580.5485
Notably Up
Slightly volatile
Gross Profit Margin1.140.9632
Fairly Up
Slightly volatile
Total Current Liabilities414 M394.3 M
Sufficiently Up
Slightly volatile
Non Current Liabilities Total213.1 M284.2 M
Way Down
Pretty Stable
Total Assets3.1 B2.9 B
Sufficiently Up
Slightly volatile
Total Current Assets1.4 B1.3 B
Sufficiently Up
Slightly volatile
Exelixis' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Exelixis' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Exelixis' financial leverage. It provides some insight into what part of Exelixis' total assets is financed by creditors.
By using current balance sheet information, investors can analyze the liability, assets, and equity on Exelixis' books and decide whether to invest or hold. Statistics such as return on equity (ROE), debt to equity (D/E) help investors determine how Exelixis deploys its capital and how much of that capital is borrowed.
Liquidity
Exelixis cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. The company currently holds 189.94 M in liabilities with Debt to Equity (D/E) ratio of 0.07, which may suggest the company is not taking enough advantage from borrowing. Exelixis has a current ratio of 5.96, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Exelixis until it has trouble settling it off, either with new capital or with free cash flow. So, Exelixis' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Exelixis sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Exelixis to invest in growth at high rates of return. When we think about Exelixis' use of debt, we should always consider it together with cash and equity.

Depreciation

27 Million
Exelixis (EXEL) is traded on NASDAQ Exchange in USA. It is located in 1851 Harbor Bay Parkway, Alameda, CA, United States, 94502 and employs 1,310 people. Exelixis is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 7.23 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Exelixis's market, we take the total number of its shares issued and multiply it by Exelixis's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Exelixis conducts business under Biotechnology sector and is part of Health Care industry. The entity has 303.19 M outstanding shares of which 8.25 M shares are currently shorted by private and institutional investors with about 3.82 trading days to cover. Exelixis currently holds about 1.53 B in cash with 333.32 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.77.
Check Exelixis Probability Of Bankruptcy
Ownership Allocation
Exelixis retains a total of 303.19 Million outstanding shares. The majority of Exelixis outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to obtain positions in Exelixis to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Exelixis. Please pay attention to any change in the institutional holdings of Exelixis as this could imply that something significant has changed or is about to change at the company. Note that regardless of who owns the company, if the true value of the entity is less than the market is willing to pay for it, you may not be able to generate positive returns over time.
Check Exelixis Ownership Details

Exelixis Stock Price Odds Analysis

Proceeding from a normal probability distribution, the odds of Exelixis jumping above the current price in 90 days from now is about 9.41%. The Exelixis probability density function shows the probability of Exelixis stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days Exelixis has a beta of 0.3229 suggesting as returns on the market go up, Exelixis average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Exelixis will be expected to be much smaller as well. Additionally, exelixis has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming NYSE Composite.
  Odds Below 23.86HorizonTargetOdds Above 23.86
90.48%90 days
 23.86 
9.41%
Based on a normal probability distribution, the odds of Exelixis to move above the current price in 90 days from now is about 9.41 (This Exelixis probability density function shows the probability of Exelixis Stock to fall within a particular range of prices over 90 days) .

Exelixis Stock Institutional Holders

Institutional Holdings refers to the ownership stake in Exelixis that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Exelixis' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Exelixis' value.
InstituionRecorded OnShares
Nuveen Asset Management, Llc2023-12-31
3.5 M
Charles Schwab Investment Management Inc2023-12-31
3.4 M
Jacobs Levy Equity Management, Inc.2023-09-30
3.3 M
First Trust Advisors L.p.2023-12-31
3.2 M
Fmr Inc2023-12-31
3.1 M
Norges Bank2023-12-31
3.1 M
Bank Of New York Mellon Corp2023-12-31
M
Meditor Group Ltd2023-12-31
2.6 M
Fuller & Thaler Asset Management Inc2023-12-31
2.6 M
Blackrock Inc2023-12-31
36 M
Vanguard Group Inc2023-12-31
31.7 M
View Exelixis Diagnostics

Exelixis Historical Income Statement

Exelixis Income Statement is one of the three primary financial statements used for reporting Exelixis's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Exelixis revenue and expense. Exelixis Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, Exelixis' EBIT is quite stable compared to the past year. Research Development is expected to rise to about 1.1 B this year, although the value of Net Income From Continuing Ops will most likely fall to about 81 M. View More Fundamentals

Exelixis Stock Against Markets

Picking the right benchmark for Exelixis stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Exelixis stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Exelixis is critical whether you are bullish or bearish towards Exelixis at a given time. Please also check how Exelixis' historical prices are related to one of the top price index indicators.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Exelixis without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Content Syndication Now

   

Content Syndication

Quickly integrate customizable finance content to your own investment portal
All  Next Launch Module

Exelixis Corporate Directors

Exelixis corporate directors refer to members of an Exelixis board of directors. The board of directors generally takes responsibility for the Exelixis' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Exelixis' board members must vote for the resolution. The Exelixis board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.
Alan GarberIndependent DirectorProfile
George ScangosIndependent DirectorProfile
Carl FeldbaumIndependent DirectorProfile
Maria FreireDirectorProfile

How to buy Exelixis Stock?

Before investing in Exelixis, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Exelixis. To buy Exelixis stock, you can follow these steps:
  • Choose a brokerage firm: You need to select a brokerage firm to buy shares of Exelixis. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
  • Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
  • Fund your account: You will need to deposit funds into your brokerage account to purchase Exelixis stock. You can do this by transferring funds from your bank account or other investment accounts.
  • Place your order: Once you have located Exelixis stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
  • Monitor your investment: After you have purchased Exelixis stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Exelixis, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Exelixis Stock please use our How to Invest in Exelixis guide.

Already Invested in Exelixis?

The danger of trading Exelixis is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Exelixis is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Exelixis. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Exelixis is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Exelixis is a strong investment it is important to analyze Exelixis' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Exelixis' future performance. For an informed investment choice regarding Exelixis Stock, refer to the following important reports:
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Exelixis. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in income.
For more information on how to buy Exelixis Stock please use our How to buy in Exelixis Stock guide.
Note that the Exelixis information on this page should be used as a complementary analysis to other Exelixis' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.

Complementary Tools for Exelixis Stock analysis

When running Exelixis' price analysis, check to measure Exelixis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Exelixis is operating at the current time. Most of Exelixis' value examination focuses on studying past and present price action to predict the probability of Exelixis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Exelixis' price. Additionally, you may evaluate how the addition of Exelixis to your portfolios can decrease your overall portfolio volatility.
Fundamental Analysis
View fundamental data based on most recent published financial statements
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Global Correlations
Find global opportunities by holding instruments from different markets
Is Exelixis' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Exelixis. If investors know Exelixis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Exelixis listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.99)
Earnings Share
0.65
Revenue Per Share
5.753
Quarterly Revenue Growth
0.131
Return On Assets
0.0355
The market value of Exelixis is measured differently than its book value, which is the value of Exelixis that is recorded on the company's balance sheet. Investors also form their own opinion of Exelixis' value that differs from its market value or its book value, called intrinsic value, which is Exelixis' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Exelixis' market value can be influenced by many factors that don't directly affect Exelixis' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Exelixis' value and its price as these two are different measures arrived at by different means. Investors typically determine if Exelixis is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Exelixis' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.